Literature DB >> 33012328

Biologics and Allergy Immunotherapy in the Treatment of Allergic Diseases.

Linda Cox1.   

Abstract

Allergic diseases represent some of the most chronic and costly chronic conditions. Medical management may require long-term pharmacotherapy, which is often associated with poor adherence. Although medications provide symptomatic control, they do not modify the allergic disease. Patients may prefer disease-modifying treatments that provide lasting benefits after discontinuation. To date, allergy immunotherapy is the only proved disease modification therapy associated with lasting benefits after discontinuation. However, allergy immunotherapy safety and efficacy has only been established in allergic rhinitis, mild to moderate asthma, and some patients with atopic dermatitis.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergy immunotherapy; Atopic dermatitis; Biologics; Mepolizumab; Omalizumab; Rhinosinusitis with nasal polyps; Subcutaneous immunotherapy; Sublingual immunotherapy

Year:  2020        PMID: 33012328     DOI: 10.1016/j.iac.2020.06.008

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  2 in total

Review 1.  The role of allergen-specific IgE, IgG and IgA in allergic disease.

Authors:  Mohamed H Shamji; Rudolf Valenta; Theodore Jardetzky; Valerie Verhasselt; Stephen R Durham; Peter A Würtzen; R J Joost van Neerven
Journal:  Allergy       Date:  2021-06-08       Impact factor: 14.710

Review 2.  Role of Damage-Associated Molecular Patterns (DAMPs/Alarmins) in Severe Ocular Allergic Diseases.

Authors:  Ken Fukuda; Waka Ishida; Tatsuma Kishimoto; Isana Nakajima; Yusaku Miura; Tamaki Sumi; Kenji Yamashiro
Journal:  Cells       Date:  2022-03-20       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.